Emerging Drug Developer: Juvaris BioTherapeutics

Juvaris BioTherapeutics

Kleiner Perkins was so impressed by the research work underway at Juvaris BioTherapeutics, the venture group ended up investing $12 million last year in the company's Series A round. And last March, Kleiner Perkins helped engineer the arrival of Grant Pickering to run the vaccine company with an eye to taking Juvaris to proof-of-concept data on a slate of vaccine development programs. 

Just weeks ago Juvaris launched its first clinical study, a Phase I trial of a vaccine adjuvant--JVRS-100--combined with a commercially available vaccine for seasonal influenza. And now the small biotech has a full slate of programs nearing the clinic. By the end of this year, the developer plans to have its first look at efficacy data in humans and a new round of venture capital in the bank. Article

Suggested Articles

Levo Therapeutics’ lead program did not beat placebo in a phase 3 study of Prader-Willi syndrome, a genetic disorder that causes insatiable hunger.

Denali is partnering with Biogen on its Parkinson's disease program, netting a $560 million upfront fee and a $465 million investment.

In the first half of 2020, the regenerative medicine sector raised $10.7 billion, more than the total it raised in 2019.